Analyst Price Targets — DMRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 11, 2026 10:01 am | Mitchell Kapoor | H.C. Wainwright | $45.00 | $20.15 | TheFly | Damora Therapeutics initiated with a Buy at H.C. Wainwright |
| May 28, 2026 11:02 am | David Nierengarten | Wedbush | $35.00 | $25.21 | TheFly | Damora Therapeutics initiated with an Outperform at Wedbush |
| April 23, 2026 8:20 pm | — | RBC Capital | $40.00 | $25.42 | TheFly | Damora Therapeutics initiated with an Outperform at RBC Capital |
Latest News for DMRA
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the completion of the redomestication of the Company from the State of Delaware to the Cayman Islands, effective on July 16, 2026. Each outstanding share of the Delaware Company's common stock…
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were…
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on June 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were…
Damora Therapeutics is focused on mutant-CALR blood diseases, with DMR-001 as its lead asset. They have approximately $562.3 million in cash, and management believes this gives them enough runway into 2029. DMRA's lead asset has potential competitors in more advanced R&D stages. This helps validate the asset class as a whole, but DMRA still needs more data of its own.
– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress – – On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively – – Appointed CEO…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DMRA.
U.S. House Trading
No House trades found for DMRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.